13C-GALACTOSE BREATH TEST AS A MEASURE OF LIVER FUNCTION

Information

  • Research Project
  • 2145988
  • ApplicationId
    2145988
  • Core Project Number
    R44DK046738
  • Full Project Number
    2R44DK046738-02
  • Serial Number
    46738
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1995 - 29 years ago
  • Project End Date
    9/29/1997 - 27 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1995 - 29 years ago
  • Budget End Date
    9/29/1996 - 28 years ago
  • Fiscal Year
    1995
  • Support Year
    2
  • Suffix
  • Award Notice Date
    9/29/1995 - 29 years ago

13C-GALACTOSE BREATH TEST AS A MEASURE OF LIVER FUNCTION

DESCRIPTION (Adapted from applicant's abstract): The liver performs diverse and important metabolic functions in human metabolism; thus, liver dysfunction can lead to serious health consequences. As a result, many different tests are used to assess liver function, but each test has limitations that compromise its value. Since galactose is primarily metabolized by the liver, the galactose breath test represents a noninvasive method of assessing liver function. In this test, 13C- galactose and a carrier dose of unlabeled galactose is administered to the patient and the appearance of 13CO2 is used as an indication of liver function. Although the literature suggests that this test is a good predictor of liver function, the clinical usefulness of the galactose breath test has not been fully evaluated due to the unavailability of 13 C galactose. The goal of this research is to produce 13C galactose and evaluate the clinical usefulness of this compound as a test of liver diseases. 13C galactose will be produced from a microalgae cultured in the presence of 13CO2. The purified 13C galactose will be used in breath tests to optimize the carrier dose of unlabeled galactose, minimize the dose of 13C galactose and determine the sensitivity and specificity of this test for assessing liver function.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    MARTEK BIOSCIENCE CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    COLUMBIA
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    21045
  • Organization District
    UNITED STATES